title: [A case of paclitaxel-resistant recurrent gastric cancer responsive to S-1 plus docetaxel].
abstract: We report the case of a patient with paclitaxel (PTX) -resistant recurrent gastric cancer who was effectively treated with S-1 plus docetaxel( DOC). A 62-year-old woman underwent total gastrectomy for Stage IV advanced gastric cancer (type 4, por 2>sig, pT4a (SE), pN3a, pP1, CY1) in 2009. Although S-1 was administered as first-line chemotherapy, recurrent peritoneal metastasis was diagnosed 22 months after surgery. S-1 plus irinotecan (CPT-11) was administered as second-line chemotherapy, and this was followed by weekly PTX (80 mg/m2) as third-line chemotherapy. However, computed tomography (CT) showed increased ascites and peritoneal wall thickening in the pelvis. As the tumor proved resistant to PTX, making the treatment ineffective, S-1( 80 mg/m2, day 1-14, q3w) plus DOC( 40 mg/m2, day 1, q3w) was initiated. Two months later, the ascites and peritoneal wall thickening in the pelvis disappeared. Twelve months after initiation of S-1 plus DOC chemotherapy, no sign of recurrence has been noted.
authors.affiliation: Dept. of Surgery, Osaka General Medical Center.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nishikawa
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Iwase
authors.forename: Toyokazu
authors.initials: T
authors.lastname: Aono
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Masaya
authors.initials: M
authors.lastname: Nomura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tamagawa
authors.forename: Chu
authors.initials: C
authors.lastname: Matsuda
authors.forename: Takashi
authors.initials: T
authors.lastname: Deguchi
authors.forename: Junji
authors.initials: J
authors.lastname: Kawada
authors.forename: Shigeyoshi
authors.initials: S
authors.lastname: Higashi
authors.forename: Koichi
authors.initials: K
authors.lastname: Deguchi
authors.forename: Yuki
authors.initials: Y
authors.lastname: Noguchi
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Okumura
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Nomura
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Fushimi
authors.forename: Mari
authors.initials: M
authors.lastname: Takagi
authors.forename: Akiko
authors.initials: A
authors.lastname: Fukui
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Fujitani
authors.forename: Shunji
authors.initials: S
authors.lastname: Endo
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077143:Docetaxel; D004338:Drug Combinations; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000627:therapeutic use; D012008:Recurrence; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid; D017239:Paclitaxel